Early use of ribavirin is beneficial in crimean-congo hemorrhagic fever

Vector-Borne and Zoonotic Diseases

Volumn 14, Issue 4, 2014, Pages 300-302

  Ozbey, Saliha Bakir ^a   Kader, Çiǧdem ^b   Erbay, Ayşe ^b   Ergönül, Önder ^c  

^a Infectious Diseases and Clinical Microbiology Department Kastamonu Dr Münif Islamoǧlu Hospital ^*  (Turkey)

^b BOZOK UNIVERSITY   (Turkey)

^c KOÇ UNIVERSITY   (Turkey)

Author keywords

Crimean Congo hemorrhagic fever; Ribavirin; Turkey

Indexed keywords

RIBAVIRIN; ANTIVIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PATIENT TRANSPORT; PRIORITY JOURNAL; SECONDARY CARE CENTER; VAGINA BLEEDING; CONFIDENCE INTERVAL; DRUG EFFECTS; EPIDEMIOLOGY; HEMORRHAGIC FEVER, CRIMEAN; HOSPITAL; MORTALITY; MULTIVARIATE ANALYSIS; NAIROVIRUS; ORAL DRUG ADMINISTRATION; RISK; SECONDARY HEALTH CARE; TREATMENT OUTCOME; TURKEY; VIROLOGY;

ADMINISTRATION, ORAL; ANTIVIRAL AGENTS; CONFIDENCE INTERVALS; FEMALE; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HOSPITALS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; RIBAVIRIN; SECONDARY CARE; TREATMENT OUTCOME; TURKEY;

EID: 84901260022     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2013.1421     Document Type: Article

References (17)

1. Arda B, Aciduman A, Johnston JC. A randomised controlled trial of ribavirin in Crimean Congo haemorrhagic fever: Ethical considerations. J Med Ethics 2012; 38:117-120.
2. Bausch DG, Hadi CM, Khan SH, Lertora JJ. Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. Clin Infect Dis 2010; 51:1435-1441.
3. Bente DA, Alimonti JB, Shieh WJ, Camus G, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J Virol 2010; 84:11089-11100.
4. Cevik MA, Elaldi N, Akinci E, Onguru P, et al. Preliminary study to evaluate the effect of intravenous ribavirin treatment on survival rates in Crimean-Congo hemorrhagic fever. J Infect 2008; 57:350-351.
5. Duygu F, Kaya T, Baysan P. Re-Evaluation of 400 Crimean-Congo hemorrhagic fever cases in an endemic area: Is ribavirin treatment suitable? Vector Borne Zoonotic Dis 2012; 12:812-816.
6. Ergonul O, Celikbas A, Dokuzoguz B, Eren S, et al. Characteristics of patients with Crimean-Congo hemorrhagic fever in a recent outbreak in Turkey and impact of oral ribavirin therapy. Clin Infect Dis 2004; 39:284-287.
7. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. Antiviral Res 2008; 78:125-131.
8. Ergonul O. DEBATE (see Elaldi N et al, Efficacy of oral ribavirin treatment in Crimean-Congo haemorrhagic fever: A quasi-experimental study from Turkey. J Infect 2009; 58: 238-244).
9. Biases and misinterpretation in the assessment of the efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever. J Infect 2009; 59:284-286; author reply 286-289.
10. Ergonul O. Crimean-Congo hemorrhagic fever virus: New outbreaks, new discoveries. Curr Opin Virol 2012; 2:215-220.
11. Fisher-Hoch SP, Khan JA, Rehman S, Mirza S, et al. Crimean Congo-haemorrhagic fevertreated with oral ribavirin. Lancet 1995; 346:472-475.
12. Izadi S, Salehi M. Evaluation of the efficacy of ribavirin therapy on survival of Crimean-Congo hemorrhagic fever patients: A case-control study. Jpn J Infect Dis 2009; 62:11-15.
13. Koksal I, Yilmaz G, Aksoy F, Aydin H, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Eastern Black Sea region in Turkey. J Clin Virol 2010; 47:65-68.
14. Mardani M, Jahromi MK, Naieni KH, Zeinali M. The efficacy of oral ribavirin in the treatment of Crimean-Congo hemorrhagic fever in Iran. Clin Infect Dis 2003; 36:1613-1618.
15. Ozkurt Z, Kiki I, Erol S, Erdem F, et al. Crimean-Congo hemorrhagic fever in Eastern Turkey: Clinical features, risk factors and efficacy of ribavirin therapy. J Infect 2005; 52:207-215.
16. Paragas J, Whitehouse CA, Endy TP, Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. Antiviral Res 2004; 62:21-25.
17. Sharifi-Mood B, Metanat M, Ghorbani-Vaghei A, Fayyaz-Jahani F, et al. The outcome of patients with Crimean-Congo hemorrhagic Fever in Zahedan, southeast of Iran: A comparative study. Arch Iran Med 2009; 12:151-153.